158 related articles for article (PubMed ID: 30119268)
1. Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerbrovascular risk: A systematic review of human clinical trials and in vivo animal studies.
Hoxha M; Lewis-Mikhael AM; Bueno-Cavanillas A
Biomed Pharmacother; 2018 Oct; 106():956-965. PubMed ID: 30119268
[TBL] [Abstract][Full Text] [Related]
2. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
Hoxha M; Rovati GE; Cavanillas AB
Eur J Clin Pharmacol; 2017 Jul; 73(7):799-809. PubMed ID: 28374082
[TBL] [Abstract][Full Text] [Related]
3. Leukotriene receptor antagonists for eczema.
Ferguson L; Futamura M; Vakirlis E; Kojima R; Sasaki H; Roberts A; Mori R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD011224. PubMed ID: 30343498
[TBL] [Abstract][Full Text] [Related]
4. Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children.
Brodlie M; Gupta A; Rodriguez-Martinez CE; Castro-Rodriguez JA; Ducharme FM; McKean MC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD008202. PubMed ID: 26482324
[TBL] [Abstract][Full Text] [Related]
5. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of montelukast's efficacy for preventing post-bronchiolitis wheezing.
Peng WS; Chen X; Yang XY; Liu EM
Pediatr Allergy Immunol; 2014 Mar; 25(2):143-50. PubMed ID: 24118637
[TBL] [Abstract][Full Text] [Related]
7. The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
Marschallinger J; Altendorfer B; Rockenstein E; Holztrattner M; Garnweidner-Raith J; Pillichshammer N; Leister I; Hutter-Paier B; Strempfl K; Unger MS; Chishty M; Felder T; Johnson M; Attems J; Masliah E; Aigner L
Neurotherapeutics; 2020 Jul; 17(3):1061-1074. PubMed ID: 32072462
[TBL] [Abstract][Full Text] [Related]
8. The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients.
Di Salvo E; Patella V; Casciaro M; Gangemi S
Pulm Pharmacol Ther; 2020 Feb; 60():101875. PubMed ID: 31837440
[TBL] [Abstract][Full Text] [Related]
9. Montelukast in pediatric asthma management.
Walia M; Lodha R; Kabra SK
Indian J Pediatr; 2006 Apr; 73(4):275-82. PubMed ID: 16816486
[TBL] [Abstract][Full Text] [Related]
10. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease.
Ingelsson E; Yin L; Bäck M
J Allergy Clin Immunol; 2012 Mar; 129(3):702-707.e2. PubMed ID: 22244598
[TBL] [Abstract][Full Text] [Related]
11. [Montelukast].
Münzel F; Mühlhäuser U; Eschenhagen T
Dtsch Med Wochenschr; 2002 Nov; 127(44):2337-9. PubMed ID: 12410440
[No Abstract] [Full Text] [Related]
12. Assessing risk: Data from montelukast clinical trials.
Kelsay K
J Allergy Clin Immunol; 2009 Oct; 124(4):697-8. PubMed ID: 19815115
[No Abstract] [Full Text] [Related]
13. Leukotriene receptor antagonist for prolonged non-specific cough in children.
Chang AB; Winter D; Acworth JP
Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD005602. PubMed ID: 16625643
[TBL] [Abstract][Full Text] [Related]
14. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients.
Virchow JC; Mehta A; Ljungblad L; Mitfessel H
J Asthma; 2010 Nov; 47(9):986-93. PubMed ID: 20858152
[TBL] [Abstract][Full Text] [Related]
15. Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.
Han B; Zhang YY; Ye ZQ; Xiao Y; Rasouli J; Wu WC; Ye SM; Guo XY; Zhu L; Rostami A; Wang LB; Zhang Y; Li X
Immunology; 2021 Jun; 163(2):185-200. PubMed ID: 33480040
[TBL] [Abstract][Full Text] [Related]
16. A review of montelukast in the treatment of asthma and allergic rhinitis.
Nayak A
Expert Opin Pharmacother; 2004 Mar; 5(3):679-86. PubMed ID: 15013935
[TBL] [Abstract][Full Text] [Related]
17. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
Wallin J; Svenningsson P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070609
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
Angelova-Fischer I; Tsankov N
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):115-9. PubMed ID: 16200338
[TBL] [Abstract][Full Text] [Related]
19. Leukotriene-receptor antagonists.
Lipworth BJ
Lancet; 1999 Jan; 353(9146):57-62. PubMed ID: 10023966
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene E
Lazarinis N; Bood J; Gomez C; Kolmert J; Lantz AS; Gyllfors P; Davis A; Wheelock CE; Dahlén SE; Dahlén B
J Allergy Clin Immunol; 2018 Oct; 142(4):1080-1089. PubMed ID: 29518425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
